Cancer
Cancer Ongoing 2021 North Shore NSW

DREAM3R

The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.

Trial overview

Disease
DREAM3R
Topic
DREAM3R
Description
Durvalumab (MEDI4736) with chemotherapy as first line treatment in advanced pleural Mesothelioma - A phase 3 Randomised trial.
Eligibility criteria

Untreated stage IV Mesothelioma, please enquire for more details.

Study details

The treatment is comparing standard of care chemotherapy to chemotherapy with Atezolizumab, the study is randomised with a ratio of 2:1. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.

Location

North Shore NSW